New York State Teachers Retirement System Has $34.16 Million Position in Cencora, Inc. (NYSE:COR)

New York State Teachers Retirement System reduced its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 1.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 152,049 shares of the company's stock after selling 2,603 shares during the period. New York State Teachers Retirement System owned about 0.08% of Cencora worth $34,162,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Lake Street Advisors Group LLC grew its position in shares of Cencora by 1.3% during the third quarter. Lake Street Advisors Group LLC now owns 3,415 shares of the company's stock worth $769,000 after buying an additional 43 shares in the last quarter. Venturi Wealth Management LLC increased its position in shares of Cencora by 1.0% in the 3rd quarter. Venturi Wealth Management LLC now owns 4,447 shares of the company's stock worth $1,001,000 after purchasing an additional 46 shares during the last quarter. Prime Capital Investment Advisors LLC raised its stake in shares of Cencora by 1.2% in the 3rd quarter. Prime Capital Investment Advisors LLC now owns 3,768 shares of the company's stock valued at $848,000 after purchasing an additional 46 shares in the last quarter. Shepherd Financial Partners LLC lifted its position in shares of Cencora by 0.9% during the fourth quarter. Shepherd Financial Partners LLC now owns 5,441 shares of the company's stock worth $1,223,000 after purchasing an additional 46 shares during the last quarter. Finally, J.W. Cole Advisors Inc. grew its stake in Cencora by 1.3% in the third quarter. J.W. Cole Advisors Inc. now owns 3,669 shares of the company's stock worth $826,000 after purchasing an additional 48 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have commented on COR. Robert W. Baird increased their target price on Cencora from $287.00 to $292.00 and gave the stock an "outperform" rating in a report on Thursday, November 7th. Barclays raised their price target on shares of Cencora from $263.00 to $290.00 and gave the stock an "overweight" rating in a research report on Thursday, November 7th. Mizuho started coverage on shares of Cencora in a research note on Wednesday, December 4th. They set an "outperform" rating and a $280.00 price objective on the stock. JPMorgan Chase & Co. boosted their price objective on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research report on Friday, January 24th. Finally, Evercore ISI increased their target price on Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research report on Thursday, February 6th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $277.90.

Insider Transactions at Cencora

In related news, Chairman Steven H. Collis sold 50,000 shares of the firm's stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the completion of the sale, the chairman now directly owns 326,557 shares in the company, valued at approximately $79,670,111.29. This trade represents a 13.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Silvana Battaglia sold 1,678 shares of the company's stock in a transaction on Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the transaction, the executive vice president now directly owns 20,329 shares in the company, valued at $4,649,648.88. This represents a 7.62 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 10.80% of the company's stock.

Cencora Price Performance

NYSE:COR traded up $3.93 during midday trading on Wednesday, hitting $245.37. 1,553,062 shares of the stock were exchanged, compared to its average volume of 1,509,604. The company has a market capitalization of $47.58 billion, a price-to-earnings ratio of 34.90, a P/E/G ratio of 1.30 and a beta of 0.49. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a one year low of $214.77 and a one year high of $262.26. The business has a 50-day moving average price of $238.75 and a two-hundred day moving average price of $237.41.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Sell-side analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 3rd. Stockholders of record on Friday, February 14th will be given a dividend of $0.55 per share. The ex-dividend date of this dividend is Friday, February 14th. This represents a $2.20 annualized dividend and a dividend yield of 0.90%. Cencora's dividend payout ratio (DPR) is 31.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.